Taken together, the superior PK profile observed for damoctocog alfa pegol, compared with rurioctocog alfa pegol, in the current study has potential clinical significance in relation to protection from bleeds in patients with hemophilia A. These data suggest patients may benefit from the higher FVIII activity levels and longer time to reach thresholds achieved with damoctocog alfa pegol compared with rurioctocog alfa pegol, using similar doses and dose intervals. This evidence concerns the gene F8 and hemophilia A.